

Entreprise leader dans la recherche et les biotechnologies





Entreprise leader dans la recherche et les biotechnologies

Entreprise de biotechnologie avec un excellent bilan de sécurité de plus de 2 500 traitements cliniques. La société conçoit, fabrique et commercialise des produits de filtration sanguine par affinité. Un nouveau dispositif d'hémofiltration très innovant qui utilise une technologie biomimétique brevetée et exclusive pour éliminer rapidement les bactéries, les champignons, les toxines bactériennes, les virus, les cytokines pro-inflammatoires et les médiateurs de la septicémie d'un patient atteint d'une infection sanguine.

Appel à l'investissement

Des millions de patients sont touchés par le marché mondial du sepsis, soit au nord de 30 millions de cas chaque année.

D'autres applications de cette technologie peuvent être utilisées comme contre-mesure aux attaques par armes biologiques (COVID), au cancer PDAC, pour prévenir les effets secondaires de l'utilisation de l'ECMO et de la circulation extracorporelle dans les diagnostics, les banques de sang et les biotraitements.

Un bénéfice net courant de seulement 10 fois pourrait valoriser l'entreprise jusqu'à 40 milliards de dollars d'ici la fin de 2028.

Opportunité de croissance

Une gestion solide

Marges bénéficiaires brutes > 85 %

BUSINESS TYPE

Pharmaceutique

COUNTRY

États-Unis

BUSINESS ID

L#20240619

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



WWW.MERGERSCORP.COM